[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585766":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":156,"collaborators":158,"id":166,"slug":167,"hasResults":168,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":168,"sex":174,"minAge":175,"maxAge":23,"enrollmentInfo":176,"targetDuration":23,"studyType":179,"phases":180,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":43,"whyStopped":23,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":202},{"fullName":5,"class":6},"Duke University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(IRIS-CKD Management Program): Education","ACTIVE_COMPARATOR","Education: Participants will receive targeted educational materials related to their stage of CKD, including recommendations for potential GDMT to discuss with their primary care provider.",[13],"Other: (IRIS-CKD Management Program): Education",{"label":15,"type":10,"description":16,"interventionNames":17},"(IRIS-CKD Management Program): GDMT","Management: Participants will receive targeted educational materials, along with GDMT prescription, dose titration, and laboratory monitoring by a pharmacist\u002FAPP, as necessary, with guidance from a centralized algorithm and oversight from a nephrologist site PI.",[13,18],"Other: (IRIS-CKD Management Program): GDMT",[20,24],{"type":6,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.",[9,15],null,{"type":6,"name":15,"description":25,"armGroupLabels":26,"otherNames":23},"Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.",[15],[28],{"name":29,"affiliation":5,"role":30},"Neha Pagidipati, MD","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":36},"Gretchen Sanders, MSN","CONTACT","919 6687829","gretchen.sanders@duke.edu",{"name":38,"role":34,"phone":23,"phoneExt":23,"email":39},"Monica Leyva, MS","monica.leyva@duke.edu",[41,62,75,92,109,124,144],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University of Alabama","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-86.80249,33.52066,{"lat":53,"lon":52},[56,60],{"name":57,"role":34,"phone":58,"phoneExt":23,"email":59},"Sarah Machado","205-934-7649","smachado@uabmc.edu",{"name":61,"role":30,"phone":23,"phoneExt":23,"email":23},"Clare Lyas, MD",{"facility":63,"status":43,"city":64,"state":65,"zip":66,"country":47,"countryCode":48,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Orlando Health","St. Petersburg","Florida","33701",{"type":50,"coordinates":68},[69,70],-82.67927,27.77086,{"lat":70,"lon":69},[73],{"name":74,"role":30,"phone":23,"phoneExt":23,"email":23},"Timothy Marsh, DO",{"facility":76,"status":43,"city":77,"state":78,"zip":79,"country":47,"countryCode":48,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"University of Michigan","Ann Arbor","Michigan","48109",{"type":50,"coordinates":81},[82,83],-83.74088,42.27756,{"lat":83,"lon":82},[86,90],{"name":87,"role":34,"phone":88,"phoneExt":23,"email":89},"Angie Westover","734-936-6467","funke@med.umich.edu",{"name":91,"role":30,"phone":23,"phoneExt":23,"email":23},"Ilka Decker, MD",{"facility":93,"status":43,"city":94,"state":95,"zip":96,"country":47,"countryCode":48,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Essentia Institute of Rural Health","Duluth","Minnesota","55805",{"type":50,"coordinates":98},[99,100],-92.10658,46.78327,{"lat":100,"lon":99},[103,107],{"name":104,"role":34,"phone":105,"phoneExt":23,"email":106},"Haley Messenger","218-786-2077","haley.messenger@essentiahealth.org",{"name":108,"role":30,"phone":23,"phoneExt":23,"email":23},"Sreedhar Devathi, MD",{"facility":5,"status":43,"city":110,"state":111,"zip":112,"country":47,"countryCode":48,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Durham","North Carolina","27707",{"type":50,"coordinates":114},[115,116],-78.89862,35.99403,{"lat":116,"lon":115},[119,122],{"name":120,"role":34,"phone":23,"phoneExt":23,"email":121},"Kim Cicio","kimberly.cicio@duke.edu",{"name":123,"role":30,"phone":23,"phoneExt":23,"email":23},"John Middleton, MD",{"facility":125,"status":43,"city":126,"state":127,"zip":128,"country":47,"countryCode":48,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Houston Methodist","Houston","Texas","77030",{"type":50,"coordinates":130},[131,132],-95.36327,29.76328,{"lat":132,"lon":131},[135,139,142],{"name":136,"role":34,"phone":137,"phoneExt":23,"email":138},"Daphne Medina","713-744-2016","damedina2@houstonmethodist.org",{"name":140,"role":34,"phone":23,"phoneExt":23,"email":141},"Steven Puckett","srpuckitt@houstonmethodist.org",{"name":143,"role":30,"phone":23,"phoneExt":23,"email":23},"Peter Nguyen",{"facility":145,"status":43,"city":146,"state":127,"zip":147,"country":47,"countryCode":48,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Baylor Scott & White","Temple","76508",{"type":50,"coordinates":149},[150,151],-97.34278,31.09823,{"lat":151,"lon":150},[154],{"name":155,"role":30,"phone":23,"phoneExt":23,"email":23},"Tariq Tariq, MD",{"type":157,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[159,162,164],{"name":160,"class":161},"Bayer","INDUSTRY",{"name":163,"class":161},"Boehringer Ingelheim",{"name":165,"class":161},"Eli Lilly and Company","100585766","implementation-program-to-improve-screening-and-management-for-ckd-in-diabetes-iris-ckd-program-2-100585766",false,"NCT06906640","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)","IRIS-CKD","Inclusion Criteria:\n\n* (CKD Management)\n\n  * Adults with type 2 diabetes (T2D)\n  * Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)\n  * Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):\n\n    * UACR \\>300 mg\u002Fg or\n    * eGFR \\\u003C45 ml\u002Fmin\u002F1.73 m2 or\n    * UACR ≥30 mg\u002Fg with eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m2\n  * Receiving \\\u003C100% GDMT at baseline. For patients with UACR \\\u003C30 mg\u002Fg, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi\u002FARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).\n\nExclusion Criteria:\n\n* (CKD Management)\n\n  * Type 1 diabetes\n  * Most recent eGFR \\\u003C20 ml\u002Fmin\u002F1.73 m2\n  * Prior kidney transplant\n  * Autosomal dominant polycystic kidney disease (ADPKD)\n  * Active pregnancy or plans for conception within 1 year","ALL","18 Years",{"count":177,"type":178},420,"ESTIMATED","INTERVENTIONAL",[181],"NA","IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.",[184,185,186],"Chronic Kidney Disease(CKD)","Type 2 DM","Type 2 Diabetes Mellitus (T2DM)",[188,189,190,191,192],"CKD","T2DM","T2D","Type 2 Diabetes","Chronic kidney disease","2026-06-15",{"date":195,"type":196},"2026-06-16","ACTUAL",{"date":198,"type":196},"2025-10-28",{"date":200,"type":178},"2027-04-01",{"name":5,"class":6},7]